EGFR and cancer: TNBC is a suitable entity for targeted delivery of anti-EGFR–Ils-dox: (i) EGFR is often and robustly overexpressed in TNBC, (ii) in vitro studies have provided evidence of high efficacy of anti-EGFR-ILs-dox in EGFR overexpressing cancer cell lines14,15, and (iii) anthracyclines and doxorubicin in particular are widely accepted and active agents for first line palliative therapy in this cancer entity.